文献速递脊柱关节炎

依那西普与甲氨蝶呤单药或联合治疗银屑病关节炎的患者报告结局

Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination.
PubMed 文献 · RMD Open · 2021-01-01

该48周3期随机对照试验比较甲氨蝶呤单药、依那西普单药及两药联合治疗银屑病关节炎,第24周时依那西普单药或联合治疗在患者整体评估、关节疼痛评估及SF-36生理综合评分上较甲氨蝶呤单药改善更显著,部分患者报告改善达到MCID的比例更高。

要点

  • 依那西普单药或联合治疗在PtGA、PtGAJP和SF-36 PCS较甲氨蝶呤单药改善更显著(p≤0.05)。
  • 达到MCID改善比例:PtGA依那西普vs甲氨蝶呤p=0.005;PtGAJP联合vs甲氨蝶呤p=0.038。
  • 第24周PROs达到年龄性别匹配常模值的比例范围:甲氨蝶呤单药20.8%–51.0%,依那西普单药30.9%–48.8%,联合30.6%–52.3%。

核心结论

  • 依那西普单药或甲氨蝶呤联合依那西普较甲氨蝶呤单药在多个患者报告结局上从基线改善更显著。
  • 患者报告结局应纳入医患治疗选择讨论,以帮助确定对银屑病关节炎患者更获益的治疗。

研究设计与样本

  • 48周3期随机对照试验,比较甲氨蝶呤单药、依那西普单药及甲氨蝶呤联合依那西普治疗银屑病关节炎患者。
  • 患者报告结局按观测数据分析,未进行多重性校正,p值为描述性。

主要发现

  • 第24周,依那西普单药或联合治疗组在PtGA、PtGAJP和SF-36 PCS评分上较甲氨蝶呤单药组改善更显著(p≤0.05)。
  • 达到MCID改善的患者比例:PtGA依那西普vs甲氨蝶呤p=0.005;PtGAJP联合vs甲氨蝶呤p=0.038。
  • 第24周PROs达到年龄性别匹配常模值的比例范围:甲氨蝶呤单药20.8%–51.0%,依那西普单药30.9%–48.8%,联合30.6%–52.3%。

关键数值与推荐

  • 疗效终点包括HAQ-DI、PtGA、PtGAJP、SF-36 PCS和MCS及8个维度评分从基线的平均变化及第24周改善≥MCID的患者比例。
  • 第24周PtGA达到MCID改善比例依那西普vs甲氨蝶呤p=0.005;PtGAJP联合vs甲氨蝶呤p=0.038。
  • 第24周PROs达到年龄性别匹配常模值的比例范围:甲氨蝶呤单药20.8%–51.0%,依那西普单药30.9%–48.8%,联合30.6%–52.3%。

临床怎么用

  • 在银屑病关节炎治疗选择讨论中应纳入患者报告结局,以帮助确定更获益的治疗方案。

局限性

  • 患者报告结局按观测数据分析,未进行多重性校正,p值为描述性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We examined patient-reported outcomes (PROs) in The Study of Etanercept And Methotrexate in Patients with Psoriatic Arthritis (PsA); a 48-week, phase 3, randomised controlled trial that compared outcomes with methotrexate (MTX) monotherapy, etanercept monotherapy, and MTX+ etanercept in patients with PsA. METHODS: Efficacy endpoints included: mean changes from baseline and proportion of patients who reported improvements≥minimal clinically important difference (MCID) at week 24 in treatment groups for Health Assessment Questionnaire-Disability Index, Patient Global Assessment (PtGA), Patient Global Assessment of Joint Pain (PtGAJP) and Medical Outcomes Study Short Form-36 Questionnaire (SF-36) Physical Component Summary (PCS), and Mental Component Summary, and eight domain scores. PROs were analysed as reported (observed), without multiplicity adjustment; therefore, p values are descriptive. RESULTS: At week 24, patients receiving etanercept monotherapy or MTX+ etanercept combination reported greater improvements (p≤0.05) in PtGA, PtGAJP and SF-36 PCS scores compared with those receiving MTX monotherapy. Compared with MTX monotherapy, higher proportions of patients receiving etanercept monotherapy and combination therapy reported improvements≥MCID in PtGA (etanercept vs MTX, p=0.005) and PtGAJP (MTX +etanercept vs MTX, p=0.038). Across PROs, proportions of patients reporting scores≥age and gender-matched normative values at week 24 ranged from 20.8% to 51.0% with MTX monotherapy, 30.9% to 48.8% with etanercept monotherapy, and 30.6% to 52.3% with MTX+ etanercept combination. CONCLUSIONS: Patients receiving etanercept monotherapy or MTX+ etanercept reported greater improvements from baseline in several PROs compared with those receiving MTX monotherapy. PROs should be incorporated in discussions between patients and clinicians regarding their treatment choices as they can help determine which treatments are more beneficial in patients with PsA.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Strand V, Mease PJ, Maksabedian Hernandez EJ, et al. Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination. RMD Open. 2021. PMID: 33452180. doi:10.1136/rmdopen-2020-001484

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。